Signalling Antibodies for the Treatment of Neoplastic Disease

Por Glennie, M. J.
Publicado em 2000

Rituximab: mechanisms and applications

Por Johnson, P W M, Glennie, M J
Publicado em 2001

Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells

Por Cragg, M S, Zhang, L, French, R R, Glennie, M J
Publicado em 1999

Ex-vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 Phase I trial

Por Chowdhury, F., Johnson, P. W., Glennie, M.J., Williams, A. P.
Publicado em 2013

Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy.

Por Stevenson, F. K., Glennie, M. J., Johnston, D. M., Tutt, A. L., Stevenson, G. T.
Publicado em 1984

Characterisation of a new murine B cell lymphoma.

Por Cobb, L. M., Glennie, M. J., McBride, H. M., Breckon, G., Richardson, T. C.
Publicado em 1986

Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.

Por French, R. R., Penney, C. A., Browning, A. C., Stirpe, F., George, A. J., Glennie, M. J.
Publicado em 1995

Guidelines for the welfare and use of animals in cancer research

Por Workman, P, Aboagye, E O, Balkwill, F, Balmain, A, Bruder, G, Chaplin, D J, Double, J A, Everitt, J, Farningham, D A H, Glennie, M J, Kelland, L R, Robinson, V, Stratford, I J, Tozer, G M, Watson, S, Wedge, S R, Eccles, S A
Publicado em 2010